Who are Astra Zeneca COVID-19 vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TT, BNT162b7 Monovalent (OMI BA.4/BA.5), Famtozinameran 5 to 11 Years of age, BNT162b2 Bivalent (WT/OMI BA.1), Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, batch 1 of Ad5-nCoV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/astra-zeneca-covid-19-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Astra Zeneca COVID-19 vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Astra Zeneca COVID-19 vaccine (Astra Zeneca COVID-19 vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: viral vector vaccine. Area: Immunology.

phase 2 viral vector vaccine SARS-CoV-2 spike protein Immunology Biologic Live · refreshed every 30 min

Target snapshot

Astra Zeneca COVID-19 vaccine (Astra Zeneca COVID-19 vaccine) — Vinbiocare Biotechnology Joint Stock Company. This viral vector vaccine delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate adaptive immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Astra Zeneca COVID-19 vaccine TARGET	Astra Zeneca COVID-19 vaccine	Vinbiocare Biotechnology Joint Stock Company	phase 2	viral vector vaccine	SARS-CoV-2 spike protein
TT	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein
BNT162b7 Monovalent (OMI BA.4/BA.5)	bnt162b7-monovalent-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Famtozinameran 5 to 11 Years of age	famtozinameran-5-to-11-years-of-age	Pfizer	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose	variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (viral vector vaccine class)

Jiangsu Province Centers for Disease Control and Prevention · 3 drugs in this class
University Medical Center Groningen · 1 drug in this class
Vinbiocare Biotechnology Joint Stock Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Astra Zeneca COVID-19 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/astra-zeneca-covid-19-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab